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Abstract
Huntington’s disease (HD) is a monogenic neurodegenerative disorder resulting from a mutation in the huntingtin gene. This
leads to the expression of the mutant huntingtin protein (mHTT) which provokes pathological changes in both the central
nervous system (CNS) and periphery. Accumulating evidence suggests that mHTT can spread between cells of the CNS but
here, we explored the possibility that mHTT could also propagate and cause pathology via the bloodstream. For this, we
used a parabiosis approach to join the circulatory systems of wild-type (WT) and zQ175 mice. After surgery, we observed
mHTT in the plasma and circulating blood cells of WT mice and post-mortem analyses revealed the presence of mHTT
aggregates in several organs including the liver, kidney, muscle and brain. The presence of mHTT in the brain was
accompanied by vascular abnormalities, such as a reduction of Collagen IV signal intensity and altered vessel diameter in the
striatum, and changes in expression of Glutamic acid decarboxylase 65/67 (GAD65-67) in the cortex. Conversely, we
measured reduced pathology in zQ175 mice by decreased mitochondrial impairments in peripheral organs, restored vessel
diameter in the cortex and improved expression of Dopamine- and cAMP-regulated phosphoprotein 32 (DARPP32) in
striatal neurons. Collectively, these results demonstrate that circulating mHTT can disseminate disease, but importantly, that
healthy blood can dilute pathology. These findings have significant implications for the development of therapies in HD.
Introduction
Huntington’s disease (HD) is a monogenic neurodegen-
erative condition which presents with a complex symp-
tomatology of motor, cognitive and psychiatric
impairments [1, 2] that progresses to death 10 to 30 years
after clinical onset [3]. The main neuropathological
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hallmarks of HD relate to extensive cell loss in the stria-
tum as well as a host of brain structures, in particular the
cerebral cortex [4, 5]. Disease is driven by an autosomal
dominant pattern of inheritance and is caused by a
pathological CAG repeat expansion exceeding 35 in exon
1 of the huntingtin gene (HTT), which encodes for hun-
tingtin (HTT), a ubiquitously expressed cytoplasmic
protein [6]. This CAG elongation leads to the production
of the mutant huntingtin protein (mHTT), which is char-
acterized by an extended polyglutamine (polyQ) stretch
[7, 8]. While mHTT is classically considered to drive
pathology from within cellular populations, it is also
found in the cerebrospinal fluid (CSF), plasma and
extracellular matrix [9–13]. There is evidence that both
peripheral and extracellular mHTT may contribute to, as
well as amplify, the disease phenotype.
Although the central nervous system (CNS) is especially
vulnerable to mHTT-induced toxicity [14], several periph-
eral abnormalities have been described in HD, including
changes in protein metabolism in skeletal muscles [15],
reduction in hepatic mitochondrial function [16] and loss of
lower limb strength [17]. Notably, accumulating evidence
suggests that early changes within the peripheral immune
system may critically contribute to CNS-associated pathol-
ogy. For example, the presence of mHTT in peripheral
monocytes has been reported to correlate with disease stage
and progression of caudate atrophy in patients [18]. In fact,
alterations in components of the immune system (e.g.,
peripheral cytokine levels) have been detected as early as 16
years prior to the predicted onset of clinical symptoms [19].
Bone marrow transplantation has also been shown to confer
some improvement on behavioral deficits in mouse models
of HD (YAC128 and BACHD) [20], implying that deletion
of peripheral cells containing mHTT can improve central
pathology.
The toxicity of mHTT has long been established but in
recent years, a possible new mechanism has begun to
emerge; the concept that mHTT can propagate between
cells and template pathology in a prion-like fashion
[21, 22]. This theory builds, in part, on our observations that
mHTT aggregates can be found within fetal striatal trans-
plants in HD patients years after they were grafted [11].
More recently, we have shown that fibroblasts or induced
pluripotent stem cells (iPSCs) derived from HD patients
injected into the ventricular system result in both motor and
cognitive impairments in wild-type (WT) mice. We
have additionally shown that WT mice injected
with fibrillar forms of mHTT exon 1 protein fragments with
a 48-glutamine repeat (Httex1-Q48) into the cortical par-
enchyma developed cognitive deficits, while similar injec-
tions into the lateral ventricles of newborn R6/2
transgenic HD mice precipitated motor and cognitive phe-
notypes [23]. Another salient finding from this work was
the presence of fibrillar mHTT in structures remote from the
injection site, suggesting the spreading of mHTT [11, 13].
In an HD drosophila model, it was explicitly demonstrated,
using a FRET-based aggregate seeding assay, that the
smaller Httex1-Q97 aggregates are seeding competent [24].
The clinical relevance of these findings is highlighted by
the detection of such forms in the most affected
cerebral structures (i.e., striatum and cortex) of HD patient
brains.
The seeding capacity of mHTT has now been shown
along with neuronal toxicity in several cell models [22, 25]
as well as in in vivo paradigms (i.e. mouse, drosophila and
C. elegans) [9, 24, 26–28] and a number of putative
mechanisms of spread have been postulated, including
trans-synaptic and paracrine transmission, as well as exo-
cytosis. Although compelling evidence has been provided
for some of these mechanisms in HD, none of these studies
have evaluated transmission from sources outside of the
CNS. Here, we sought to investigate the role of circulating
mHTT and the potential contribution of peripheral path-
ways to disease pathology using a parabiosis approach
where we joined the circulatory systems of a well-
established mouse model of HD, the zQ175 mouse, with
WT littermates. Our study reveals that blood not only
serves as a vehicle of propagation for mHTT, but also that




zQ175 mice (B6J.129S1-Htttm1Mfc/190ChdiJ) and WT
littermate control mice were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA) and maintained in an
in-house colony at the Centre de Recherche du CHU de
Québec – Université Laval (CRCHUQ-UL, Québec, QC,
Canada). zQ175 mice express a chimeric mouse/human
exon 1 mHTT with approximately 190 CAG repeats and
display an HD-like phenotype [29]. Female mice were used
for all studies as male mice, including littermates, are more
prone to aggressive behavior which is incompatible with the
long-term pairing required by the parabiosis procedure [30].
β-actin Green Fluorescent Protein (GFP) mice were pro-
vided by Dr. Serge Rivest at the CRCHUQ-UL. All mice
were maintained in a temperature-controlled room (~23 °C)
with a 12/12 h (h) light/dark cycle and ad libitum access to
food and water. Animal handling, surgeries and all other
procedures were completed in accordance with the guide-
lines of the Canadian Council on Animal Care and were
approved by the Comité de Protection des Animaux du
CRCHUQ-UL.
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In vivo procedures
Surgery
Parabiosis was performed on 34 female mice at 5 months of
age to produce a total of 17 couples. Mice were randomly
divided into groups. Negative and positive control groups
(e.g. genotype, parabiosis surgery) were included in both
surgical cohorts. For each time-point of sacrifice (6, 9, and
12 months post-surgery), groups included one pair of WT/
WT and HD/HD mice. Two, four, and five pairs of WT/HD
mice were sacrificed at 6, 9, and 12 months post-parabiosis,
respectively. Surgeries were performed under aseptic con-
ditions according to previously published protocols [30].
Briefly, mice were anesthetized with 3% isoflurane and
maintained on heating pads during the procedure and
recovery to prevent loss of body heat. Mirror-image inci-
sions at the flanks of parabiotic pairs were made through the
skin. Elbow and knee joints from each parabiont were
bound together using 3–0 silk sutures (Covidien Suture,
#SS684G), while the skin was attached using 5–0 coated
vicryl sutures (Ethicon Suture, #J391H). Each mouse
received a subcutaneous injection of lidocaine–bupivacaine
(7–3.5 mg/kg) and slow-release buprenorphine (1 mg/kg)
prior to surgery as well as a subcutaneous injection of saline
after surgery to prevent dehydration. Mice were monitored
daily to ensure good overall health and recovery.
Separation of parabionts
In the initial proof of concept experiment, a β-actin GFP
mouse was paired with a WT littermate for four weeks and
then separated. For separation of the pair, mice were anes-
thetized with 3% isoflurane and subcutaneously injected
with lidocaine–bupivacaine (7–3.5 mg/kg) and slow-release
buprenorphine (1 mg/kg). The skin was incised at the site of
union to separate the animals. The resulting wound in the
corresponding lateral flanks of each mouse was closed with
5–0 coated vicryl sutures (Ethicon Suture, #J391H). Mice
were monitored daily and sacrificed one week after
separation.
Blood sampling
Submandibular blood withdrawal was performed every
3 weeks under a light and rapid 2% isoflurane anesthesia.
The submandibular vein was selected as it was accessible to
repeated sampling and sufficiently remote from the surgical
site to ensure that blood content was representative of total
blood circulation and not biased by proximity to the para-
biotic partner. At each collection, ~100 μL of blood was
retrieved with a 5 mm lancet (Goldenrod lancet,
#NC9891620) and immediately placed in tubes containing
acid citrate dextrose (ACD; 0.48% (w/v) C6H8O7, 1.32%
(w/v) Na3C6H5O7, 1.47% (w/v) C6H12O6) and Tyrode
pH 6.5 (7 mM NaHCO3, 135 mM NaCl, 3 mM KCl,
0.4 mM NaH2PO4, 1 mM MgCl2, 4.5 mM Glucose, and
18.7 mM HEPES buffer) to avoid coagulation and activa-
tion of platelets.
Hemodynamic measurements
To detect blood pressure and heart rate, we used the BP-
2000 Series II hardware system (Visitech Systems, Inc.,
Apex, NC, USA) according to previously published proto-
cols [31]. Briefly, a platform was set to 34 °C and 20
measurements per mouse were acquired daily between
13h00 and 15h30 using a tail cuff 6.35 mm in diameter and
appropriately sized holders. Mice were assessed for 10
consecutive days and the measurements of the first 7 days
(the acclimation period) as well as outliers (defined as
values [V] < [Q1− 1.5 × IQR] or > [Q3+ 1.5 × IQR], where
Q stands for quartile and IQR for interquartile range) were
excluded from analysis. Mean arterial pressure was calcu-
lated from systolic and diastolic blood pressure.
Collection and processing of blood and organ
samples
Isolation of blood components
Blood components (erythrocytes, leukocytes, platelets, and
plasma) were separated from the same tube by serial cen-
trifugation using an adaptation of previously published
protocols [32, 33].
Erythrocytes
Briefly, blood was centrifuged for 4 min at 600 × g at room
temperature (RT). The resulting pellet of erythrocytes was
washed twice with 0.9% NaCl and stored at −80 °C with a
glycerolyte solution (57% C3H8O3, 142 mM C3H5NaO3,
1 mM KCl, 25 mM Na3PO4 pH 6.8) to cryopreserve cells
and protect them from lysis. In order to perform western
blots, erythrocytes containing glycerolyte were defrosted at
RT, 9% NaCl was added drop by drop (one third of the
initial volume) and samples were incubated for 10 min at
RT. Samples were washed with 2.5% NaCl and centrifuged
at 1200 × g for 2 min prior to discarding the supernatant.
Pellets were subsequently washed once with 2.5% NaCl and
twice with 0.85% NaCl. Pellets were diluted one-to-five
with lysis buffer (Pierce, #87788) containing protease and
phosphatase inhibitor cocktail 1X final (Thermo Fisher
Scientific, #1861284). Protein concentration was measured
using a bicinchoninic acid (BCA) protein assay kit (Pierce,
#23225) according to the manufacturer instructions.
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Leukocytes
Leukocytes were obtained from the buffy coat (the thin
layer containing leukocytes lies between the erythrocytes
and plasma following a density gradient centrifugation)
after incubation with 1X BD (Lysing Buffer, BD Pharm
Lyse, #555899) for 15 min and centrifugation at 1500 × g
for 5 min at RT. The pellet was then solubilized in 25 μL of
lysis buffer (Pierce, #87788) containing 1X protease and
phosphatase inhibitor cocktail (Thermo Fisher Scientific,
#1861284).
Platelets
For platelets, the platelet-rich plasma was collected with the
addition of 1/5 volume of ACD, 1/50 volume of 0.5 M
ethylenediaminetetraacetic acid (EDTA) pH 8.0 (Fisher
BioReagents, #BP2482) and centrifuged twice for 2 min at
400 × g and 5 min at 1300 × g. The pellet was dissolved in
25 μL of Tyrode pH 6.5, 225 μL of Tyrode pH 7.4, 50 μL of
ACD, and 5 μL of 0.5 M EDTA. Platelets were centrifuged
for 5 min at 1300 × g and the pellet was dissolved in 25 μL
of lysis buffer containing 1X protease and phosphatase
inhibitor cocktail.
Plasma
Plasma collected during platelet isolation was centrifuged
for 15 min at 2500 × g at RT. Platelet-free plasma was
harvested and stored at −80 °C.
Tissue preparation At sacrifice, mice were anesthetized by
intraperitoneal injection (0.1 mL per 10 g of mouse) of
100 mg/kg ketamine and 10 mg/kg xylazine prior to intra-
cardiac perfusion with phosphate-buffered saline (PBS). At
dissection, lymph nodes, adipose tissue, lung, kidney, and
muscle were obtained from each side of the body, while
intestine, spleen, pancreas, heart, and liver were divided as
symmetrically as possible. Half of each organ was collected
for western blotting and half for immunohistochemistry
experiments. In preliminary analyses, several organs
including the intestine, heart, lung, spleen, muscle, kidney,
and liver were assessed but for complete analysis, we
selected two highly vascularized organs, the liver and kid-
ney, and one less vascularized organ, the muscle.
For immunohistochemistry, all organs were collected,
post-fixed in 4% paraformaldehyde (PFA) for 48 h and
subsequently stored in 20% sucrose in PBS at 4 °C for
cryoprotection. At the time of sectioning, brains were cut
into 25 µm thick sections using a freezing microtome, while
peripheral organs were embedded in a M-1 matrix (Thermo-
Scientific, #1310), frozen and cut into 14 µm (liver) or
10 µm (kidney and muscle) thick sections which were
mounted directly onto SuperFrost® slides (Fisher Scientific,
#22-037-246). For western blotting, organs were immedi-
ately frozen on dry ice and stored at −80 °C. Peripheral
organs were homogenized on ice with a dounce homo-
genizer potter in eight volumes of tris-buffered saline (TBS)
containing CompleteTM protease inhibitor cocktail (Roche,
#5892970001), 10 μg/ml of pepstatin A (Merck-Millipore,
#516481) and phosphatase inhibitor cocktail (Sigma-
Aldrich, P5726), as described previously [34]. Brains were
homogenized in eight volumes of lysis buffer (150 mM
NaCl, 10 mM NaH2PO4, 1% Triton X-100, 0.5%
sodium dodecyl sulfate (SDS), and 0.5% deoxycholate)
containing the same protease and phosphatase inhibitors.
After homogenization, all lysates were briefly sonicated
(3 × 10 s) and centrifuged at 100,000 × g for 20 min at 4 °C
to generate a TBS-soluble fraction that contains intracellular
(cytosolic) and extracellular proteins. Total protein in cell
lysates was then quantified using a BCA Protein Assay Kit
(ThermoFisher, #23225). After each soluble fractions’
preparation, the insoluble pellet of brain and muscle was
homogenized with RIPA buffer (50 mM Tris-HCl pH 8.0,
150 mM NaCl, 5 mM EDTA pH 8.0, 1% NP-40 (IGEPAL),
0.1% SDS, 0.5% deoxycholate) containing Halt Protease
Phosphatase Inhibitor 1X (Thermo Scientific, #1861281).
Liver and kidney pellets were processed in 1% SDS buffer
(20 mM Tris pH 7.4, 1% SDS, 1 mM EDTA, 1X protease
inhibitor cocktail (Bimake, #B14001), 1X phosphatase
inhibitor cocktail (Sigma-Aldrich, #P5726)). Samples were
then sonicated for 2 × 10 s and resuspended with a 26G
needle five times. After 30 min on ice, a BCA assay was
performed according to the manufacturer’s instructions.
Flow cytometry Before immunofluorescent labeling, Fc-
receptors were blocked to prevent nonspecific binding using
an anti-CD16/CD32 mix (BD Pharmingen, #553142) in
potassium phosphate-buffered saline (KPBS)+ 1% Fetal
Bovine Serum (Sigma-Aldrich, #F1051) for 15 min and
peripheral blood mononuclear cells were labeled on ice for
30 min with the fluorescently conjugated primary anti-
CD45 v500 antibody (1:100, BD Biosciences, #561487).
Erythrocytes were then lysed with a whole blood lysing
reagent kit (Beckman Coulter, #6603152) for 20 s and
washed with PBS. Data were acquired with a BD LSR II
flow cytometer and analyzed with FlowJo software (version
10.0.7; Tree Star). For all analyses, controls containing
GFP and v500 only were used to establish gating bound-
aries [35].
Extraction of RNA and reverse transcription One fourth of
the total hippocampus and an equally sized piece of liver
and kidney from 12-month parabiosis mice and their asso-
ciated controls were dissolved in 1 mL of TriReagentTM
(Sigma-Aldrich, #T9424). Extraction of RNA was
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performed using the Phenol/Chloroform technique, where
all centrifugation steps were performed using an Eppendorf
Centrifuge 5415R. Briefly, 200 µL of chloroform (Sigma-
Aldrich, #C2432) were added per 1 mL of TriReagentTM
and mixed vigorously by hand for 30 s. The mixture was
left to stand at RT for 2 min prior to centrifugation of
samples at 12,000 RPM for 15 min at 4 °C. This step let to
division of the solution into two phases. The upper clear
phase containing DNA was transferred to a new tube,
carefully leaving the DNA-containing interface undisturbed.
Next, 500 µL of isopropanol was added (Sigma-Aldrich,
#I9516), samples were thoroughly mixed by vortexing and
incubated at RT for 10 min. After this incubation, pre-
cipitated RNA was collected by centrifugation of samples at
12,000 RPM for 10 min at 4 °C. The supernatant was
removed and the RNA pellets were washed by adding 1 mL
of 70% ethanol (Greenfield Global, #P016EAAN). RNA
pellets were mixed by vortexing and centrifuged at 8000
RPM for 5 min at 4 °C. Supernatants were discarded, and
pellets were dried before resuspending in sterile water. To
ensure proper solubilization of RNA, samples were heated
10 min at 56 °C. DNAse treatment was performed using 1U
of DNAse (Roche, #4716728001) per 1 µg of RNA for
30 min at 37 °C according to manufacturer’s instructions.
To stop DNase reaction, samples were heated for 10 min at
70 °C with 25 mM of EDTA (Fisher BioReagents,
#BP2482-500). RNA samples were reverse-transcribed to
cDNA by incubation with 0.5 mM dNTPs (10 mM: Sigma-
Aldrich, #11277049001) and 21 ng/µL of random primer
(1.6 µg/µL: Sigma-Aldrich, #11034731001) for 5 min at
65 °C. After incubation, samples were placed on ice,
MMLV 1X buffer and 10 mM DTT (Invitrogen, #28025-
013) was added prior to heating for 2 min at 37 °C. Finally,
200U of MMLV reverse transcriptase (Invitrogen, #28025-
013) were added and samples were incubated for 10 min at
25 °C and then 50 min at 37 °C. The reaction was stopped
by heating samples for 10 min at 70 °C.
Immunoassays
For all immunoassays, appropriate buffer and secondary
antibody controls were included to ensure that all positive
staining was due to binding of the primary antibody to the
targeted antigen with no contribution from non-specific
background or secondary antibody signal.
Erenna Singulex SMC immunoassay
The MW1 polyglutamine and 2B7 N-terminal HTT
antibodies were conjugated to magnetic particles (MPs) to
a final concentration of 25 µg/mg of MPs for MW1 and
1 µg/µL for 2B7 using the Erenna capture and detection
reagent labeling kits from Merck-Millipore, following the
manufacturer’s instructions (Merck-Millipore, #03-0077-02
and #03-0076-02 respectively). Conjugated/labeled anti-
bodies were diluted in Assay Buffer (Merck-Millipore, #02-
0474-00) to 1:1200 and 1:4000 respectively, prior to per-
forming the assay which was carried out using a slightly
modified version of previously published protocols [10].
Briefly, mouse plasma samples were pre-diluted 1:10 in
complete artificial CSF and 2B7 antibody coupled, to MPs,
was added to assay buffer containing 6% bovine serum
albumin (BSA, w/v, Bioshop, #ALB001), 0.8% Triton X-
100 (v/v, Sigma-Aldrich, #T8787), 750 mM NaCl and
complete protease inhibitor in a 96-conical assay plate
(Axygen, # P-96-450V-C). The plate was sealed and incu-
bated on a shaker at RT for 1 h. Samples were washed on a
magnetic rack using a HydroFlex Microplate 8 Channel
Washer (Tecan), in 1X Erenna Wash Buffer (Merck-Milli-
pore, #02-0111-03). After washing, MPs were incubated
with MW1 detection antibody for 1 h at RT. Samples were
again washed in 1X Erenna Wash Buffer on a magnetic rack
in a HydroFlex washer. The antibody-antigen complex was
transferred to a new 96-conical assay plate to eliminate
nonspecific binding to the plastic. After buffer aspiration,
Elution Buffer B (Merck-Millipore, #02-0297-00) was
added to the plate for 5 min of incubation while shaking.
The eluted detection antibody was transferred to a Nunc
384-well analysis plate (Sigma-Aldrich, #264573) and
neutralized with Buffer D (Merck-Millipore, #02-0368-00).
The analysis plate was spun down to eliminate foaming and
bubble formation, sealed, and subsequently analyzed with
the Erenna Immunoassay System (Merck-Millipore).
Quantification of inflammatory markers
Concentrations of cytokines were determined in plasma,
liver and kidney using the Q-Plex™ Mouse Cytokine (16-
Plex) Kit (Quansys Biosciences, #110349MS). This Q-Plex
analysis was performed according to the manufacturer’s
instructions. Absorbance values were measured at 450 nm
using a myECL imager (ThermoFisher, #G2236X).
Protein electrophoresis and western blotting
For standard western blots, 30 µg of proteins were run on a
10% SDS-polyacrylamide gel at 100 V until the dye
migrated out of the gel. After migration, proteins were
transferred onto Amersham Hybond 0.45 µm poly-
vinylidene difluoride membranes (GE Healthcare,
#10600023) in Towbin buffer with 20% methanol at 130 V
for 1 h. Membranes were removed from the transfer,
blocked for 1 h in 0.5% BSA and 5% milk powder in PBS
containing 0.1% Tween 20 (PBST) and incubated overnight
(O/N) in primary antibody in the same blocking buffer.
Secondary antibodies were horseradish peroxidase (HRP)
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conjugated. HRP signal was revealed in chemiluminescence
with Immobilon Forte Western HRP Substrate (Merck-
Millipore, #WBLUF0500) using a myECL imager (Ther-
moFisher, #G2236X). Where the Odyssey imaging system
was the detection method, REVERT total protein stain (LI-
COR Biotechnology, #926-11011) was performed accord-
ing to the manufacturer’s instructions.
The detailed specification for each western blot have
been summarized in the Supplementary material and
methods (Tables S1 and S2).
Filter retardation assay
The filter retardation assay was performed in triplicate with
5 μg of tissue pellet homogenate diluted in PBS to complete
a volume of 70 μL to which 30 μL of SDS/Dithiothreitol
(DTT) mix was added (final concentration 2% SDS and
100 mM DTT). Samples were boiled at 100 °C for 5 min
and cooled to RT. A cellulose acetate membrane (Steriltech,
#1480025) was washed 2 × 5 min in 1% SDS in PBS prior
to loading. Once the apparatus was assembled (HYBRI
DOT Manifold, #1050MM), 100 μL of each sample was
loaded per well and vacuum filtered through the membrane.
Following filtration, the membrane was washed with 0.1%
SDS in PBS, removed from the equipment, dried for 30 min
and washed 3 × 5 min with 0.1% SDS and rinsed once with
PBS to remove excess SDS. The membrane was then
blocked with 5% BSA in PBS for 1 h at RT and incubated
with an anti-HTT clone EM48 antibody and anti-total HTT
N18 antibody (kindly provided by Dr. Ray Truant,
McMaster University, Canada) in 5% BSA in PBST O/N at
4 °C. Incubation in Li-Cor secondaries was performed for
45 min and membranes were visualized using the Odyssey
CLx imaging system (Odyssey; Li-Cor).
FRASE assay
The quantification of seeding-competent HTT species in
cortex homogenates was performed as previously described
[24]. In brief, frozen cortex tissue was homogenized in 10-
fold excess (w/v) of ice-cold 10 mM Tris-HCl pH 7.4, 0.8
M NaCl, 1 mM EDTA, 10% sucrose, 0.25 U/μL benzonase
and complete protease inhibitor cocktail (Roche,
#5056489001) with a dounce homogenizer. The homo-
genate was incubated for 1 h at 4 °C on a rotating wheel and
centrifuged for 20 min at 2700 × g (4 °C) to remove cell
debris. Next, cortex homogenates (5 μg total protein/repli-
cate) were added to the aggregation reaction of recombinant
sensor proteins, two soluble glutathione S-transferase (GST)
HTT exon-1 (HTTex1) fusion proteins with 48 glutamines
C-terminally fused to CyPet or YPet (1.2 µM GST-Ex1Q48-
CyPet and GST-Ex1Q48-YPet in 50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1 mM EDTA, 1 mM DTT and 14 U
PreScission Protease (GE Healthcare, #27-0843-01) per
nmol sensor proteins). To monitor the aggregation of sensor
proteins, fluorescence signals were measured every 20 min
following a 5 s pulse of vertical shaking with a Tecan M200
fluorescence plate reader at 25 °C for 30 h (CyPet donor
fluorescence at excitation (Ex): 435 nm/emission (Em):
475 nm; YPet acceptor fluorescence at Ex: 500 nm/Em:
530 nm; FRET channel (DA) was recorded at Ex:
435 nm/Em: 530 nm). FRET efficiency E (in%) was cal-
culated as follows: E= (DA-cDxDD-cAxAA)/AA with
DD= donor channel signal, AA= acceptor channel signal,
cD = donor bleed-through and cA = acceptor cross exci-
tation. Seeding effects (Δt50 [h]) were quantified by
subtracting the t50 values (time at half-maximal FRET
efficiency) of the respective sample from the negative
control. To obtain the t50 values, the aggregation
kinetics were curve fitted by Richard’s five-parameter
dose–response curve using GraphPad Prism.
y ¼ y0 þ y1  y0
1þ 10 Logxbxð ÞHillSlopeð ÞS
 
Immunohistochemistry
Detection of mHTT aggregates in peripheral organs After
tissue processing, sections were immunoperoxidase stained
with the HTT antibody S829 (kindly provided by Dr. Gillian
Bates, University College London, United Kingdom).
Briefly, sections were rinsed in 0.1 M Tris-HCl pH 7.5 with
0.9% NaCl (TBS) followed by antigen retrieval with citrate
buffer pH 6.2 for 30 min at 90 °C. After the tissue was
cooled, endogenous biotin was blocked using a 3%
hydrogen peroxide solution (H2O2) and sections were
incubated in primary antibody (S829, 1:2000) diluted in
blocking solution (TBS, 2% Horse serum (Vector Labora-
tories, #S-2000) and 0.1% Triton™ X-100) O/N at RT.
Sections were then incubated for 1 h at RT in biotinylated
horse anti-goat secondary antibody (1:500, Vector Labora-
tories, #BA9500) in blocking solution, followed by incu-
bation with avidin-biotin peroxidase complex (ABC-HRP
complex) using the Vectastain Elite ABC kit (Vector
Laboratories, #PK-6100), as recommended by the manu-
facturer. The signal was revealed with 3,3-diaminobezidine
(DAB, Sigma-Aldrich, #D5905) in 0.1 M Tris-HCl pH 7.5.
Finally, sections were rinsed in water and counterstained
in eosin (Sigma-Aldrich, #HT110116). They were then
dehydrated in ascending grades of ethanol, cleaned in
Citrisolv (Decon Laboratories, #1601) and coverslipped
with DPX mounting media (Electron Microscopy Sciences,
#13512).
Detection of mHTT aggregates in CNS Free-floating sec-
tions were rinsed in 0.2M PBS, placed in 3% H2O2 for
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30 min and blocked with 4% normal goat serum (NGS,
Wisent Bioproducts, #053-150), 0.4% Triton™ X-100 and
1% BSA. Sections were then incubated O/N at 4 °C with
anti-HTT clone EM48 (1:500, Merck-Millipore,
#MAB5374) in blocking buffer. After primary antibody
incubation, samples were washed 3 × 8 min in 0.2 M PBS
and incubated for 1 h at RT in biotinylated goat anti-mouse
secondary antibody (1:1500, Vector Laboratories,
#BA9200) diluted in blocking solution and washes were
repeated. After PBS washes, brain slices were placed in
ABC-HRP complex solution (Vector Laboratories, # PK-
6100), as recommended by the manufacturer. Following
washes in acetate imidazole 0.2 M pH 7.2, the sections were
revealed with DAB (Sigma-Aldrich, #D5905) mixed with
2.6% NiSO4 to enhance signal. Sections were mounted on
SuperFrost® slides (Fisher Scientific, #22-037-246), rinsed
in water and counterstained with 0.5% methyl-green
(Sigma-Aldrich, #323829) in 0.1 M sodium acetate pH
4.2. Slides were dehydrated and cover-slipped in the same
manner as described for peripheral organs.
Detection of neurons and microglia in the striatum and
cortex Free-floating sections were rinsed in 0.1 M PBS,
placed in 3% H2O2 for 30 min and blocked with 5% NGS
(Wisent Bioproducts, #053-150) and 0.1% Triton X-100 in
PBS 0.1 M. Sections were then incubated O/N at 4 °C with
one of the following antibodies in blocking buffer; anti-Iba1
(1:1000, Wako, #019-19741), anti-calbindin (1:1000,
Sigma-Aldrich, #C9848) or anti-DARPP32 (1:1000, Cell
signaling, #2306S). After primary antibody incubation,
samples were washed 3 × 8 min in 0.1 M PBS and incubated
for 1 h at RT in either biotinylated goat anti-mouse sec-
ondary antibody (1:1500, Vector Laboratories, #BA9200)
or biotinylated goat anti-rabbit secondary antibody (1:1500,
Vector Laboratories, #BA1000) diluted in blocking solution
and washes were repeated. After PBS washes, brain slices
were placed in ABC-HRP complex solution (Vector
Laboratories, # PK-6100), as recommended by the manu-
facturer. Following washes in Tris 0.05 M pH 7.6, the
sections were revealed with DAB (Sigma-Aldrich,
#D5905). Sections were mounted on slides and air-dried
prior to dehydration and coverslipping.
Evaluation of blood vessel permeability Slices were
washed in 0.1 M PBS and post-fixed in 4% PFA pH 7.4 for
1 h. They were put in 3% H2O2 for 30 min and incubated in
a blocking solution of 5% NGS (Wisent Bioproducts, #053-
150) and 0.1% Triton™ X-100 in 0.1 M PBS for 30 min.
They were subsequently incubated with Immunoglobulin G
(IgG) antibody (biotinylated goat anti-mouse IgG, 1:500,
Vector Laboratories, #BA-9200) in blocking solution for
45 min and placed in a solution containing ABC-HRP
complex (Vectastain Elite ABC kit; Vector Laboratories,
#PK-6100) for 45 min. The bound antibodies were visua-
lized by placing the sections in a 0.05M Tris buffer solution
containing 0.5 mg/ml of DAB (Sigma-Aldrich, #D5905)
and 0.1% of 30% H2O2 (Sigma-Aldrich, #H1009). Sections
were mounted on slides and air-dried prior to dehydration
and coverslipping.
Immunofluorescence
Sections were rinsed three times in KPBS and an antigen
retrieval step with citrate buffer pH 6.2 for 30 min at 80 °C
was performed. Sections were then washed 3 × 5 min in
KPBS, blocked in 0.5% BSA, 0.4% Triton™ X-100 and
10% normal donkey serum (Sigma-Aldrich, #D9663) in
KPBS for 30 min and incubated with Collagen IV (1:500,
Merck-Millipore, #AB769) primary antibody diluted in
blocking solution O/N at 4 °C. The next morning, sections
were washed in KPBS and incubated with donkey anti-goat
Alexa Fluor 488 conjugated (Invitrogen, #A-11055) sec-
ondary antibody at 1:500 in blocking solution for 2 h at RT.
After rinsing, sections were incubated in KPBS containing
0.022% 4′,6-diamidino-2-phenylindole (DAPI, Molecular
Probes, #D3571) for 7 min, washed and mounted on
SuperFrost® slides (Fisher Scientific, #22-037-246). After
completing mounting, slides were placed in 70% ethanol,
covered with autofluorescence eliminator reagent (Merck-
Millipore, #2160) for 5 min prior to washing in 70% ethanol
three times and coverslipping with Fluoromount-G.
Quantitative reverse transcription polymerase chain
reaction
Reverse transcription quantitative polymerase chain reac-
tion (RT-qPCR) using Master Mix SybrGreenER (Ther-
mofisher, #11762100) was performed in the Corbett Rotor
Gene RG-3000. The following primers were used: murine
glyceraldehyde 3-phosphate dehydrogenase (gapdh) for-
ward GAACATCATCCCTGCATCCA and reverse CCAG
TGAGCTTCCCGTTCA; WT HTT: forward CAGGTCC
GGCAGAGGAACC and reverse TTCACACGGTCTTTC
TTGGTGG; mHTT: forward GCCCGGCTGTGGCTGA
and reverse TTCACACGGTCTTTCTTGGTGG. PCR
efficiency (E) and coefficients of determination (R2) for
each primer were validated using five serial 2-fold dilution
points where Ct(s) were plotted versus the logarithm of
dilution according to previous publication: [36] gapdh pri-
mers E= 105%, R2= 0.915; WT HTT primers E= 105%
R2= 0.957; mHTT primers E= 109% R2= 0.978. The RT-
qPCR reaction consisted of 10 µL Master Mix SybrGreener,
1 µL of each primer, 6 µL of sterile water and 2 µL of pre-
viously prepared cDNA (cDNA hippocampus= 40 ng/µL;
cDNA liver and kidney= 120 ng/µL). Samples were
amplified according to the following program: initial
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denaturation for 10 min at 95 °C, followed by 40 cycles of
15 s at 95 °C and 60 s at 59 °C. Subsequently, a dissociation
curve (melting curve) analysis was applied with one cycle at
95 °C for 15 s, 60 °C for 1 min and 0.5 °C ramp rate to
95 °C to confirm specific amplification. Minus reverse
transcription or water controls were included in each run
and uniformly displayed a lack of signal. Analysis of rela-
tive gene expression data were performed using the 2−ΔΔCT
method, as previously described[37], using gapdh as the




Immunoblot band intensity was evaluated with either Ima-
geJ Analysis Software (National Institutes of Health, http://
imagej.nih.gov.acces.bibl.ulaval.ca/ij) or the Odyssey Ima-
ging System (Odyssey; Li-Cor, Lincoln, NE). Protein sig-
nals were corrected to GAPDH, Vinculin or REVERT
signal intensity to control for differences in loading. To
normalize samples run on separate gels, all data is shown
as % of non-parabiotic controls.
Stereological counts
Stereology was performed using the Optical Fractionator
probe (Stereo Investigator, Microbrightfield) installed on an
E800 Nikon microscope in order to count mHTT positive
aggregates in the periphery and relevant neuronal and glial
populations in the brain. Perimeters of the peripheral organs
and brain structures were outlined under a 2× or 4×
objective lens respectively, using the tracing contour option.
Counts in the periphery were performed by a blinded
investigator under a 60× objective lens within the defined
perimeter every 14th (liver), 12th (kidney), or 10th (muscle)
section in a series of S829-stained sections throughout the
entire organ of each mouse. In the periphery, the counting
frame was set to 75 × 75 with a grid layout of 500 × 500 for
the kidney and 750 × 750 for the liver and the muscle. For
counts in the brain, two independent blinded investigators
counted every 10th section for a total of three striatal and
three cortical sections. The counting frame was set to 100 ×
100 and the grid layout to 300 × 300, to count between 100
and 120 squares per structure using a 20× objective lens.
Vascular abnormalities
Angiopathy and leakage were quantified in mice sacrificed
12 months post-surgery. For angiopathy, three slices of the
cortex and striatum equally distributed along the rostro-
caudal axis were selected. For leakage, three consecutive
brain slices from the widest part of the striatum separated by
250 µm (~0.50; 0.25 and 0.00 mm from bregma) were
analyzed. To evaluate angiopathy, we acquired one picture
of a fixed size (606 × 606 µm) in both the cortex and stria-
tum using an Imager Z.2 AXI0 confocal microscope (Zeiss,
Oberkochen, Germany). Fiji (version 2.0) software was
used to calculate signal intensity, for both leakage and
angiopathy, which was then averaged to obtain a mean
intensity value for each image. To assess Feret diameter,
density and area fraction of the blood vessels, the “analyze
particles” tool was used. From the diameter measurements,
we divided the population of blood vessels into two sub-
populations: blood vessels with a diameter above and below
10 μm. The branch number and length was calculated using
the Fiji (version 2.0) plug-in “analyze skeleton” according
to previously published protocols [38]. Briefly, the binary
image was skeletonized and subsequently analyzed with the
aforementioned plug-in. To measure the amount of IgG in
the parenchyma, photomicrographs were taken using Pic-
ture Frame software (Microbrightfield, Williston, VT)
linked to an E800 Nikon microscope (Nikon Instruments,
Melville, NY). Pictures were subsequently transformed into
binary images and the percentage of staining within the area
of interest was calculated using the “area fraction” tool in
Fiji (version 2.0).
Statistical analysis
Animals underwent surgery in two distinct batches, with
processing and data collection also conducted separately.
All data were reproducible between both individual animals
and batches. No sample size calculations were performed as
animal numbers needed to be kept to a minimum due to the
tight ethical regulation surrounding the parabiosis para-
digm. Prior to commencing our data analysis, an outlier was
defined as a data point more than 1.5 interquartile ranges
below the first quartile, or 1.5 interquartile ranges above the
third quartile. Two-way ANOVAs followed by Tukey’s or
Sidak’s post-hoc tests were used for all analyses of multiple
groups (genotype of the mouse of interest vs. genotype of
the partner) at a single time-point. When unequal variances
were detected between groups, or when the data did not
have a normal distribution, the statistical analysis was
modified according to the type of data being analyzed. For
two-way ANOVA analyses with unequal variance, each
genotype was isolated and assessed by one-way ANOVA
with Holm–Sidak’s post-hoc tests or an unpaired t-test
depending on the number of groups. For one-way ANOVA
analyses, Kruskal–Wallis with Dunn post-hoc tests were
performed when analyzing the effect of the partner geno-
type—referred to as treatment effect throughout the text—
on the mouse of interest at a specific time point.
Mann–Whitney tests were used when comparing two
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groups at a single time point. All data are shown as the
mean ± SEM. Statistical significance was set at p < 0.05. All
statistical analyses were performed using Prism (6.0c;
Graph-Pad Software Inc., La Jolla, CA). The Service de
Consultation Statistique de l”Université Laval (Québec,
Québec, Canada) was also consulted for some of the sta-
tistical analyses.
Results
To test the capacity of circulating blood to disseminate
mHTT to various organs, we opted for the use of parabiosis,
an approach which consists of surgically connecting two
animals by their flank to create anastomosis of blood ves-
sels. As a proof of concept, we first performed a study in
which we surgically connected a GFP-expressing mouse to
a WT littermate for four weeks. At the end of the four
weeks, the mice were separated. Blood sampling was per-
formed at day 5 and at separation (Fig. S1a). GFP+ leu-
kocytes, analyzed by flow cytometry (Fig. S1b), were found
to be present in equal number to non-fluorescent leukocytes
at both time points. These experiments confirmed that the
parabiosis procedure allowed efficient transfer of blood
cells between paired mice and that these cells could be
identified in the circulation of either animal.
Having established the efficacy of the surgical procedure,
experiments were conducted using the zQ175 mouse line
that expresses a chimeric mHTT gene with human exon 1 at
endogenous levels [29]. Experimental groups were gener-
ated from the same WT/HD pair. Depending on the geno-
type of the mouse being analyzed, the groups were referred
to as either WT(HD) or HD(WT). The controls included WT
and HD parabionts (WT(WT) and HD(HD)) and non-
parabionts (WT(NP) and HD(NP)). To understand the time
required for detection of mHTT in the circulation and
organs of the parabionts, blood was collected starting 3 days
post-surgery and pairs were sacrificed at 6, 9, and
12 months post-surgery (Fig. 1a). To confirm the transfer of
mHTT between mice, the presence of mHTT within all
types of blood cells-erythrocytes, leukocytes and platelets-
as well as plasma (Fig. 1b-e) was measured by western blot
and Singulex assay, respectively. By day 3 post-surgery,
mHTT could be detected in both WT(HD) and HD(WT) mice.
From day 7 onward, the number of mHTT containing ery-
throcytes was similar in both groups (Fig. 1b), as were the
number of mHTT-containing leukocytes (Fig. 1c) and pla-
telets (Fig. 1d). Furthermore, mHTT was detected in the
plasma of WT(HD) mice at both 6 and 12 months but not in
WT mice that did not undergo parabiosis (Fig. 1e), indi-
cating the efficacy of the procedure. We then began
assessment of peripheral organs by selecting two highly
vascularized organs, the liver and kidney, and one less
vascularized tissue, the muscle. The soleus muscle of the
leg was chosen as it is characterized by a particularly high
number of mitochondria making it more susceptible to
oxidative stress. Western blot analysis of WT HTT and
mHTT showed that parabiosis neither resulted in detectable
levels of mHTT in WT mice nor affected the levels of WT
HTT in any of the organs evaluated 12 months post-surgery
(Fig. 1f–h). However, in the kidney, mHTT was reduced in
both parabiosis groups as compared with the non-parabiosis
HD controls (Fig. 1g) indicating that the parabiosis proce-
dure itself could impact mHTT levels.
While soluble mHTT is clearly present in both blood
cells and plasma, it is not necessarily the most likely form to
accumulate in organs. We therefore also assessed insoluble
mHTT using filter retardation assay and immunohis-
tochemistry. No accumulation of mHTT aggregates was
observed in WT(HD) mice at any time point in the liver
(Fig. S2a), kidney (Fig. S2b) or muscle (Fig. S2c) when
measured using the filter retardation assay. However, this
assay did not differentiate between HD(NP) and WT(NP) and
only demonstrated a significant genotype effect in the kid-
ney (Fig. S2b). The absence of differences suggests that the
large SDS-insoluble aggregates measured using this method
are not present in peripheral organs. In contrast, mHTT
aggregates were detectable by immunohistochemistry as
early as 6 months post-surgery in the liver (Fig. 2a), kidney
(Fig. 2b) and muscle (Fig. 2c) of WT(HD) mice. In all
organs, a certified pathologist confirmed the presence of
aggregates within cells and further specified the cell types as
hepatocytes and tubular cells of the liver and kidney,
respectively. In the muscle, aggregates were determined to
be present within myocytes, generally in the nuclei. Nine
and 12 months post-surgery, HD(WT) mice showed fewer
aggregates in the liver than HD(HD) (Fig. 2d). In the kidney,
both parabiosis groups, HD(WT) and HD(HD), had less
aggregates than age-matched mice that did not undergo
parabiosis (Fig. 2e). Analysis of the muscle did not reveal
group differences (Fig. 2f). The consistency of the soluble
and insoluble mHTT decrease after parabiosis in the kidney
suggests that both changes may be mediated by the same
mechanism. For this reason, HTT and mHTT mRNA levels
were quantified in the kidney and the liver. In the liver,
parabiosis with WT mice led to increased expression of
both HTT and mHTT in HD(WT) mice although mHTT
aggregates were reduced in this tissue (Fig. S2d). In the
kidney, no genotype or group effects were present for HTT
indicating that any changes in protein level was likely due
to increased protein degradation. An interesting additional
finding was the presence of mHTT RNA in WT(HD) mice
despite the absence of detectable soluble protein (Fig. S2e).
mHTT RNA has previously been found to be present in
blood cells [39] and it is therefore likely that such cells were
the source of mHTT in this organ. The increased sensitivity
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of RT-qPCR as compared with western blotting could
explain the detection of mHTT mRNA in the absence of
soluble mHTT protein, or the mRNA may have been pre-
sent but not transcribed.
Having observed the presence of mHTT protein and
mRNA in WT mice, peripheral organs were evaluated for
features of cellular stress. Given the predominance of
mitochondrial dysfunction in HD patients, the levels of
translocase of the outer membrane 40 (TOM40) and cyto-
chrome c were evaluated. TOM40 is an outer membrane
transport protein that has previously been shown to be
decreased in mouse models of HD; [40] a decrease that has
been linked to increased cytochrome c release and apoptosis
[41]. In the liver, no difference in TOM40 was observed
between groups (Fig. 3a), but for cytochrome c, there was a
main effect of interaction between genotype and treatment
(F2,14= 4.818, p= 0.026) (Fig. 3b), with a trend towards
increased levels of cytochrome c in HD(NP) mice as com-
pared with WT(NP), which was absent in HD(WT) (Fig. 3b). In
the kidney, there was an overall effect of genotype and
treatment on the amount of protein detected (Genotype:
F1,13= 34.29, p < 0.0001; Treatment: F2,13= 3.960, p=
0.0454) with HD(NP) showing higher levels than WT(NP)
(Fig. 3c). This increase was absent in HD(WT) mice which
did not significantly differ from WT controls (Fig. 3c).
Similar genotype and treatment effects were observed for
Fig. 1 HTT/mHTT levels in blood and peripheral organs of
parabionts. a Following parabiosis surgery, blood samples were
collected every 3 weeks and pairs of mice were periodically sacrificed
between 6 and 12 months. The presence of mHTT was evaluated
within b erythrocytes, c leukocytes, d platelets and e plasma at the
indicated time points. HTT/mHTT protein content in f liver, g kidney,
and h muscle was quantified by western blot at 12 months post-surgery
(n= 2 for same genotype pairs and n=5 for multi-genotype pairs).
Data are expressed as mean ± SEM with data points indicating values
for each animal. Statistical analyses were performed using b a three-
way ANOVA or c–h two-way ANOVA with Tukey’s or Sidak’s post-
hoc tests. **p < 0.01; ***p < 0.001; ****p < 0.0001. d day, EP event
photons, GAPDH Glyceraldehyde 3-phosphate dehydrogenase, HD
Huntington’s disease, HTT huntingtin protein, kDa kilodalton, m
mutant, mo month, NP non-parabiotic mice, PolyQ polyglutamine
stretch of mHTT protein, S/B ratio signal/background ratio, WT
wild-type.
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cytochrome c (Genotype: F1,13= 6.406, p= 0.0251; Treat-
ment: F2,13= 15.81, p= 0.0003) (Fig. 3d) with a striking
effect of parabiosis in both WT and HD mice; all parabiotic
mice showing lower levels of cytochrome c than the non-
parabiotic controls. While the TOM40 data was unexpected
and differed from previously published reports, the cyto-
chrome c data in the kidney and liver corroborates the
changes in insoluble mHTT levels and suggests that the
reduction of mHTT may contribute to the decrease in
cytochrome c. In the muscle, the TOM40 levels were more
consistent with previous reports [40] as there was an overall
decrease in HD mice (Genotype: F1,14= 37.97, p < 0.0001)
(Fig. 3e). Importantly, this genotype effect was diminished
in HD(WT) when compared with HD(HD) mice using a t-test
(p= 0.032) (Fig. 3e). Consistent with the lack of changes of
insoluble mHTT in the muscle, no group differences were
detected for cytochrome c in this tissue (Fig. 3f).
After establishing the presence of changes in the per-
iphery, we shifted our focus to the vasculature as it is an
important connection between the periphery and the CNS.
The vasculature of the striatum and cortex, the primarily
targeted brain structures in HD [14], were therefore eval-
uated for changes (Figs. 4 and S3). For this assessment,
Collagen IV, as part of the basement membrane, was
selected as a marker of normal vascular structure as pre-
vious publications have shown that cerebral amyloid
angiopathy is measurable with this label [42, 43]. In the
cortex, no differences in signal intensity of Collagen IV
were distinguished between any experimental groups at the
latest time point (Fig. S3a). In the striatum at 12 months
Fig. 2 mHTT propagation and dilution in peripheral organs of
parabionts. a Liver, b kidney and c muscle from parabiotic pairs were
assessed for the presence of mHTT aggregates using immunohis-
tochemistry at 6 months post-surgery. Representative photo-
micrographs and quantifications of stereology are shown for HD(WT)
mice and controls in d liver, e kidney, and f muscle at 9 and 12 months
post-surgery. mHTT aggregates are indicated by arrowheads. Insets
depict an optical magnification of the identified aggregates. Scale bars
= 50 μm, inset = 12.5 μm. Data are expressed as mean ± SEM with
data points indicating values for each animal. N= 4 for same genotype
pairs and n= 9 for multi-genotype pairs. Statistical analyses were
performed using a one-way ANOVA followed by Holm–Sidak’s post-
hoc tests. *p < 0.05; ****p < 0.0001. HD Huntington’s disease, HTT
huntingtin protein, m mutant, NP non-parabiotic mice, WT wild-type.
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post-parabiosis, Collagen IV intensity was significantly
higher in WT(WT) mice than in any other experimental
group, including WT(HD) (Fig. 4a). Since an increase in
signal intensity of Collagen IV with age is a physiological
process [44], this is indicative of pathological changes in
WT(HD) mice. This interpretation is further strengthened by
the presence of differences between WT(WT) and HD(HD)
mice which are consistent with previously published
reports of vascular changes in mouse models of HD, as
well as in patients [45]. One of the previously reported
changes in vasculature in HD patients is an increased
density of vessels [45]. To determine if the decrease
in Collagen IV signal intensity was secondary to a change
in vessel number, we evaluated the density and the area
covered by Collagen IV+ structures (Figs. 4b, c and
S3b, c). However, neither parameter was altered suggesting
that the changes in signal intensity likely reflect reductions
in protein expression.
While the density of blood vessels has been reported to
increase in patients, additional structural changes, such as
decreased diameter and altered morphology of branches,
have been reported in the R6/2 transgenic mouse model of
HD [45]. Therefore, we assessed other structural parameters
and found that vessel diameter (Fig. S3d) and population
percentage (Fig. S3e) as well as number of vessel branches
(Fig. S3f) and branch length (Fig. S3g) showed genotype or
interaction effects in the cortex (Fig. S3h) (diameter-Gen-
otype: F1,8= 5.441, p= 0.0480; populations by diameter-
Genotype: F1,8= 9.007, p= 0.0170; branching-Interaction:
F1,7= 8.302, p= 0.0236; branch length-Interaction: F1,8=
12.08, p= 0.0084). No genotype specific changes were
observed for any of these parameters in the striatum (dia-
meter-Genotype: F1,8= 1.620, p= 0.2388; populations by
diameter-Genotype: F1,8= 0.6476, p= 0.4442; branching-
Genotype: F1,8= 2.051, p= 0.1900; branch length-Interac-
tion: F1,8= 15.64, p= 0.0042) (Fig. 4d–h). For all analyses,
the exact parameter measured is pictorially represented
(Figs. 4i and S3i). In the cortex, parabiotic-partner equally
influenced the vessel morphology with WT(HD) mice dis-
playing a phenotype that was partway between WT(WT) and
Fig. 3 Mitochondrial function




Cytochrome c 9 months post-
parabiosis for a, b liver,
c, d kidney, and e, f muscle.
Data are expressed as mean ±
SEM with data points indicating
values for each animal. N= 2
for same genotype pairs and n=
5 for multi-genotype pairs.
Statistical analyses were
performed using a two-way
ANOVA with Tukey’s or
Sidak’s post-hoc tests. *p <
0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. Cyt c
cytochrome c, HD Huntington’s
disease, kDa kilodalton, NP
non-parabiotic mice, TOM40
translocase of the mitochondrial
outer membrane 40, WT wild-
type.
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HD(HD) for both measures of diameter (Fig. S3d, e), indi-
cating that sharing blood with an HD mouse detrimentally
impacted the cortical vasculature despite the absence of
changes in Collagen IV signal intensity. HD(WT) mice were
similar to HD(HD) mice for all measures, except branch
length (Fig. S3g). Here, partnership with a WT mouse
substantially reduced the length of individual branches such
that HD(WT) mice had similar branch length as WT controls.
For vessel branching (Fig. S3f), while no significant dif-
ferences were observed, a strong trend towards a reduction
Fig. 4 Impact of parabiosis on striatal vasculature in parabionts.
a Quantification and representative images of mean fluorescence
intensity for Collagen IV at 12 months post-surgery. b Density,
c number, d diameter and e vessel population by diameter were
assessed as well as f branching and g branch length. h Representative
images of striatal vasculature and i depiction of quantification meth-
ods. Scale bars = a 25 μm, h–i 40 μm, i, high magnification 20 μm.
Data are expressed as mean ± SEM with data points indicating
values for each animal. N= 2 for same genotype pairs and n= 5 for
multi-genotype pairs. Statistical analyses were performed using a two-
way ANOVA with Tukey’s or Sidak’s post-hoc tests. For d,
e unpaired t-test were completed *p < 0.05; **p < 0.01; ***p < 0.001.
HD Huntington’s disease; WT wild-type.
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was detected in HD(WT) mice. This reduction was well
below all other groups which would generally indicate a
detrimental change, except that it was coincident with the
restoration of branch length which suggests the two findings
may be linked. When treatment effects were assessed in the
striatum, similar results for branch length were observed
(Fig. 4g), but in this region, this did not reflect a return to
WT(WT) values. In the striatum, both WT(HD) and HD(WT)
groups were significantly lower than their respective control
pairs suggesting that this effect was specific to animals
partnered to a mouse of a different genotype. Finally, HD
(WT) mice had improvements in blood vessel diameter, both
in the absolute size and overall population (Fig. 4d, e). In
both the striatum and the cortex, measures of diameter
showed the clearest impact of partner blood. In the cortex,
WT(HD) displayed significant impairments while in the
striatum, HD(WT) mice demonstrated significant improve-
ments. In both structures, the effects on branch length and
number were more complex.
In addition to structural changes in blood vessels, increased
permeability of the BBB has previously been described in
mouse models of HD, including decreased expression of tight
junction proteins, leakage and infiltration of leukocytes
[45, 46]. Given the possible interactions between increased
permeability and migration of peripheral cells into the brain,
the effects of parabiosis on both of these factors was assessed
using claudin 5, as an indicator of BBB permeability, and
intercellular adhesion molecule (ICAM), as a marker of
endothelial cell activation and recruitment of peripheral blood
cells to the CNS. In the cortex, a significant effect of genotype
was observed for claudin 5 (Fig. 5a) (Genotype: F1,17=
12.25, p= 0.0027) but this phenomenon was not observed for
ICAM (Genotype: F1,17 = 0.7917, p= 0.3860) (Fig. 5b),
although HD(WT) mice had a significant increase in ICAM
levels (Fig. 5b). These results are similar to those of the
periphery suggesting that perfusion with healthy blood may
yield protection against disease-associated pathology irre-
spective of site. In the striatum, no effect of genotype was
observed for claudin 5 but parabiosis generated complex
effects (Fig. 5c). WT(WT) mice had increased expression of
claudin 5 compared with both WT(NP) and WT(HD). The dif-
ference between WT(NP) and WT(WT) is most likely the result
of the parabiosis procedure. Since the WT(HD) and WT(WT)
groups both underwent the same procedure, the decreased
levels of claudin 5 in the WT(HD) mice could be a sign of
increased vascular deficits in this model, as has been pre-
viously reported for R6/2 mice [45]. Similarly to claudin 5,
ICAM levels were increased by the presence of parabiosis in
WT(WT) mice but not in WT(HD) mice (Fig. 5d). The changes
in markers of BBB integrity were associated with increased
leakage, as measured by the presence of IgG antibodies in the
parenchyma, in HD(HD) mice as compared with WT(WT)
groups in both the cortex (Fig. 5e, f) and striatum (Fig. 5g, h).
This increase was absent or reduced in HD(WT) in
both structures, indicating a beneficial effect of sharing cir-
culation with a WT mouse (Fig. 5e, g) (Interaction: Cortex
F2,20= 198.8, p < 0.0001; Striatum F2,20= 11.09, p=
0.0006). The presence of this increase only in parabionts
implies that the parabiosis procedure interacts with the gen-
otype to specifically exacerbate barrier opening in the HD
animals. The absence of this phenotype in HD(WT) mice
indicates that this exacerbation is prevented by the presence of
healthy blood.
In the context of HD, pathology in the CNS is the
hallmark of disease phenotype and it is therefore critical
to determine if the sharing of blood containing patholo-
gical elements also impacts this organ. To this end, wes-
tern blots were performed in the cortex (Fig. 6a), striatum
(Fig. S4a) and hippocampus (Fig. S4b) to determine if
soluble mHTT was present, but no signal was detected
in WT(HD) mice. However, an effect of parabiosis on the
expression of WT HTT was seen as early as 6 months
post-surgery in the cortex (Fig. 6a). At this time point,
parabiosis decreased the expression of WT HTT in both
HD and WT mice, with the greatest decreases present in
WT(HD) and HD(WT) groups. Twelve months post-para-
biosis, this pattern shifted and WT(WT) and HD(HD) had
increased expression of WT HTT as compared with their
respective non-parabiotic controls in the cortex (Fig. 6b).
Support for the relevance of this decrease in soluble
mHTT detected by western blot analysis comes from the
FRASE assay which measures particularly toxic forms
of the mHTT proteins [24]. Using this method, inclusion
of WT(NP) material did not influence the aggregation of
sensor proteins beyond what was observed in the buffer
control (Fig. 6c, upper panel). However, the addition of
lysates from both HD(NP) and HD(WT) groups accelerated
the aggregation of sensor proteins indicating HTT seeds
were present to accelerate the reaction kinetics (con-
centration-dependent left shift of the HD curves). Quan-
tification of the seeding effects (Fig. 6c, lower panel)
revealed a decrease in the seeding capacity in the HD(WT)
group, suggesting a beneficial effect of the WT mouse on
its partner in relation to cortical mHTT toxicity.
In the striatum, the only significant change was in WT
HTT for WT(HD) mice where these animals had a significant
increase as compared with the two control WT groups
(Fig. S4a). In the hippocampus at 12 months, a similar
decrease to that observed in the cortex at 6 months was
detected in parabiotic animals, except WT(WT) mice, which
displayed a decrease in WT HTT when compared with their
non-parabiosis partner mice (Fig. S4b). Together, these
findings suggest a complex interaction between parabiosis,
genotype and partner genotype but all indicate that the
parabiosis procedure itself impacts WT HTT in the brain.
Western blots further showed a diminishment of mHTT in
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the cortex of HD(WT) mice but failed to detect an increase in
mHTT in the same brain structure at 6 months post-surgery
(Fig. 6a) or in the cortex, striatum and hippocampus
12 months post-surgery in WT(HD) mice (Figs. 6b and S4a,
b). RT-qPCR analysis suggests that, similarly to the per-
iphery, these changes occur at a post-transcriptional level,
as no changes in mRNA were detected between any groups
(Fig. S4d). Despite the absence of mHTT RNA and protein
in WT(HD) mice, detection of insoluble mHTT by immu-
nohistochemistry and filter retardation assay both indicate
that mHTT is present in the brains of WT(HD) mice
(Figs. 6d, e and S4c).
The presence of insoluble mHTT in the brain is strong
evidence that mHTT can be transported from the circulatory
system to the CNS but it does not indicate if there are func-
tional consequences to this. To assess the potential impacts of
Fig. 5 BBB disruption in parabionts. Quantifications and immuno-
blots of tight junction proteins a, c claudin 5 and b, d ICAM measured
in the a, b cortex and c, d striatum at 12 months post-surgery.
e, g Quantifications and f, h representative images of immunohisto-
chemical detection of IgG in the e, f cortex and g, h striatum of
parabiotic mice 12 months post-surgery. Scale bar = 50 μm. Data are
expressed as mean ± SEM with data points indicating values for each
animal. N= 2 for same genotype pairs and n= 5 for multi-genotype
pairs. Statistical analyses were performed using a two-way ANOVA
with Tukey’s post-hoc tests for all graphs except b for which a one-
way ANOVA with Holm–Sidak’s post-hoc test was used to analyze
the HD groups. *p < 0.05; **p < 0.01; ****p < 0.0001. BBB
blood–brain barrier, GAPDH Glyceraldehyde 3-phosphate dehy-
drogenase, HD Huntington’s disease, ICAM intercellular adhesion
molecule, IgG immunoglobulin G, kDa kilodalton, NP non-parabiotic
mice, WT wild-type.
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mHTT in the cerebral tissue of parabionts, markers of various
cell populations were assessed. In the cortex, NeuN [47],
VGLUT1 [48, 49] and GAD65-67 [50, 51] were measured by
western blot, as typical markers of cell populations targeted in
HD. Consistent with disease features, an overall decrease was
detected in NeuN (Fig. 7a) (Genotype: F1,14= 13.86, p=
0.0023) and GAD65-67 in HD mice (Fig. 7c) (Genotype:
F1,13= 20.15, p= 0.0006), but not in VGLUT1 (Fig. 7b)
(Genotype: F1,15= 0.3294, p= 0.5745). For NeuN, no effect
of parabiotic partner was observed in WT mice, but for
GAD65-67, a decrease was detected in WT(HD) mice indi-
cating that the presence of mHTT led to a detectable detri-
mental effect on this cellular population. Conversely, an
improvement in HD(WT) mice was detected for both of these
markers (Fig. 7a, c) but not for VGLUT1 (Fig. 7b). A similar
analysis was performed in the striatum for corticostriatal
terminals (VGLUT1) [49], projection neurons (DARPP32)
[52] and interneurons (calretinin) [53]. A genotype specific
decrease was absent in VGLUT1 (Genotype: F1,13= 3.808,
p= 0.0729) (Fig. 7d), DARPP32 (Fig. 7e) (Genotype:
F1,13= 1.344, p= 0.2671) and calretinin (Fig. 7f) (Genotype:
F1,14= 1.247, p= 0.2828). No change was detected in
WT(HD) mice for any marker, but a protective effect in HD(WT)
mice was observed for DARPP32, a well-established hall-
mark of pathology [54]. For this marker, an increase of signal
intensity was present in HD(WT) as compared with both
HD(HD) and HD(NP). The differences between VGLUT1
findings in the striatum and cortex suggests that the overall
genotype effect observed in the cortex is not specifically
linked to a change in the corticostriatal pathway, but may
Fig. 6 Impact of parabiosis on cortical HTT/mHTT levels of
parabionts. Quantifications and immunoblots of soluble HTT content
at a 6 and b 12 months after parabiosis. c Quantification of the seeding
capacity of the mHTT using a FRASE assay. d Representative images
of immunohistochemical detection of EM48+ mHTT aggregates
within the CNS (indicated by arrowheads). e Representative images
(showing two animals per group) and quantifications of filter retar-
dation assays of cortical samples 9 and 12 months post-surgery. Scale
bar = 50 μm. Data are expressed as mean ± SEM with data points
indicating values for each animal. N= 2 for same genotype pairs and
n= 5 for multi-genotype pairs. Statistical analyses were performed
using a, b a two-way ANOVA with Tukey’s or Sidak’s post-hoc tests
or e unpaired students t-tests. For c, statistical significance was
assessed by a one-way ANOVA followed by a Tukey’s multiple
comparison. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
CNS central nervous system, EM48 anti-mHTT protein antibody,
FRET fluorescence resonance energy transfer, h hour, HD Hunting-
ton’s disease, HTT huntingtin protein, kDa kilodalton, m mutant, NP
non-parabiotic mice, N18 anti-huntingtin protein antibody, WT wild-
type.
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instead reflect changes in multiple pathways, such as corti-
cocortical, corticothalamic and corticostriatal projections.
To better understand if the changes in cell markers by
western blot reflected cell dysfunction or death, stereology
was performed to count the number of calbindin+ inter-
neurons in the cortex as well as DARPP32+ cells in the
striatum (Fig. S5a, b). Calbindin was used for stereology as
GAD65-67 staining is not conducive to counting and nearly
Fig. 7 Impact of parabiosis on neuronal and glial cell populations
in parabionts. Quantifications and representative immunoblots of a–c
cortical and d–f striatal neuronal markers as well as g microglia and h
astrocytes assessed at 9 months post-surgery. Data are expressed as
mean ± SEM with data points indicating values for each animal. N=2
for same genotype pairs and n=5 for multi-genotype pairs. Statistical
analyses were performed using a two-way ANOVA with Tukey’s or
Sidak’s post-hoc tests for all graphs except (a) for which a one-way
ANOVA with Holm-Sidak’s post-hoc test was used to analyze the HD
groups. *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001.
DARPP32 Dopamine- and cAMP-regulated phosphoprotein 32,
GAD65/67 Glutamic acid decarboxylase 65/67, GAPDH Glycer-
aldehyde 3-phosphate dehydrogenase, GFAP Glial fibrillary acidic
protein, HD Huntington’s disease, Iba1 Ionized calcium binding
adapter molecule, kDa kilodalton, NeuN neuronal nuclei, NP non-
parabiotic mice, VGLUT1 vesicular glutamate transporter 1, WT wild-
type.
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all calbindin+ cells in the neocortex are GABAergic inter-
neurons, making these results comparable [55]. Both
GAD65-67 protein expression and the number of
calbindin+ neurons significantly differed between geno-
types in the cortex (Genotype: F1,15= 6.086, p= 0.0262)
(Fig. S5a). In addition, HD(WT) mice still showed a strong
trend towards an increase in cell number as compared with
HD(NP). The largest difference between the two findings was
the lack of significance between WT and HD groups by
post-test in the cell count. For DARPP32, no group or
treatment differences were detected in cell number (Geno-
type: F1,14= 0.2363, p= 0.6344; Treatment: F2,14= 2.802,
p= 0.0947) (Fig. S5b). Overall, none of these cell counts
showed a significant main effect of treatment, genotype or
interaction. This was anticipated as changes in protein
expression frequently occur prior to overt cell death and
generally indicate changes in cell functionality.
Finally, the effect on non-neuronal cell types was mea-
sured by western blot detection of Iba1 and GFAP. For
Iba1, a paradoxical increase was observed in WT(WT) mice
compared with WT(NP) and WT(HD) mice (Fig. S6a). When
microglia number was assessed in the same region, WT(WT)
mice still differed, but in this case, a decrease was observed,
although this did not reach statistical significance. When
considered together, the two analyses are indicative of fewer
cells with a higher concentration of Iba1 (Fig. S5c). No
other genotype or group differences were observed for
either marker in the cortex (Figs. S6a, b and S5c). In the
striatum, HD(HD) mice demonstrated a significant increase in
Iba1 which was absent in both HD(WT) and HD(NP) mice
(Fig. 7g). No significant group differences were detected in
the cell count (Fig. S5d). These findings suggest that
parabiosis itself can increase microglial inflammation but
this can be alleviated by the presence of blood from an
animal of a different genotype. Only a minor genotype
difference was measured for GFAP, although an increase
was present in HD(WT) mice as compared with all other
groups (Genotype: F1,13= 4.911, p= 0.0451) (Fig. 7h).
In summary, the data indicate that the sharing of blood
circulation between WT and HD mice has a number of con-
sequences on both genotypes. In WT mice, propagation of
mHTT was confirmed in both peripheral organs and the brain,
and this propagation was associated with increased cellular
and organ impairments including reduction of GAD65-67
expression and features of angiopathy (Fig. 8). In HD mice,
these changes were largely beneficial and indicative of atte-
nuated pathology. These improvements included decreased
peripheral insoluble mHTT, decreased BBB leakage and
increased expression of mitochondrial and neuronal disease-
relevant markers (Fig. 8). To investigate potential mechanisms
by which the improvements in HD(WT) mice and impairments
in WT(HD) mice may be mediated, we tested two different
hypotheses: (1) that changes in arterial blood pressure would
promote an efflux of the mutant protein from the CSF to the
blood and thus help its clearance and (2) that changes in
peripheral inflammation may mediate both the central and
peripheral effects. However, when we analyzed the different
features of blood pressure in WT and transgenic animals
(Fig. S7a–c), we did not observe significant differences except
for heart rate (Fig. S7d). For inflammation, we focused our
analysis on cytokines that have previously been reported to
increase with disease progression such as interleukin-4 (IL-4),
IL-5, IL-6, IL-10 and Tumor Necrosis Factor α (TNF-α) as
well as cytokines which correlate with specific aspects of
disease pathology such as TNF-α concentrations and the rate
of motor symptom progression [19]. When we evaluated the
plasma, all tested cytokines (excepting TNF-α) showed a trend
towards an increase in WT(HD) mice, but only IL-4 and IL-10
reached statistical significance (Fig. S8a). This overall ten-
dency suggests that an HD partner elevates disease-related
cytokines in WT mice beyond what is expected from the
surgical procedure. Since no differences were detected
between WT(NP) and HD(NP) mice, this increase is unlikely to
be an artifact due to high expression in the HD partner. This is
further supported by the lack of change in HD(WT) animals
although the parabiosis procedure itself showed a trend
towards increased cytokines in both HD parabiotic groups
(Fig. S8a). To determine if inflammation changes were present
in organs, we also measured cytokines in the liver and kidney
(Fig. S8b, c). In the liver, cytokines showed a robust genotype
difference in the absence of significant effects of treatment
(Fig. S8b). In the kidney (Fig. S8c), the effect of genotype was
absent but an effect of treatment was present in IL-5 (Treat-
ment: F2,11= 4.519, p=0.0369) and TNF-α (Treatment: F2,11=
4.213, p=0.0438), and approached significance for IL-4, 6
and 10 (Treatment: F2,11= 3.167, p=0.0820, F2,11= 3.257,
p=0.0775, F2,10= 3.791, p=0.0595 respectively). Together,
these findings indicate that parabiosis impacts inflammation
and that this modulation influences some, but not all, of the
observed phenotypes.
Discussion
The work presented here was initiated to determine if the
genetic product of HD, namely mHTT, could spread
through the circulatory system and thereby cause disease-
relevant pathological features. Using a parabiosis approach
in which a surgical intervention allows two animals to share
their circulatory systems, we demonstrate that mHTT pro-
tein and mRNA originating from an HD mouse can travel
from the bloodstream into various tissues of a non-
transgenic mouse; a phenomenon which extends to the
appearance of signs of angiopathy and changes in neuronal
markers in the brain of the WT animals. In addition to
shedding light on the role of circulating mHTT in disease
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Fig. 8 Summary of findings. BBB blood–brain barrier, CNS central
nervous system, DARPP32 dopamine- and cAMP-regulated phos-
phoprotein 32, GAD65/67 glutamic acid decarboxylase 65/67, HD
huntington’s disease, HTT huntingtin protein, Iba1 ionized calcium
binding adapter molecule, ICAM intercellular adhesion molecule, IL
interleukin, m mutant, NeuN neuronal nuclei, NP non-parabiotic
mice, TOM40 translocase of the outer membrane 40, WT wild-type,
√ presence, ∅ absence, ↑ increase, ↓ decrease.
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dissemination, one of the critical findings of our experiment
is the demonstration that sustained perfusion of healthy
blood leads to improvements of several hallmarks of HD,
both at the level of the periphery and brain.
In peripheral organs, insoluble mHTT aggregates were
detectable within cells of all tested tissues as early as
6 months post-surgery. The presence of these aggregates
confirms that mHTT can be taken up and retained by cells.
However, this data does not discriminate whether the uptake
is of whole aggregates, or if soluble mHTT is taken up and
subsequently converted into an aggregate.
The most likely hypothesis is that free mHTT present in
the plasma is transferred into the organs and over time,
accumulates into aggregates. This process requires
6 months which is the same amount of time it takes for
HTTExon1Q48 fibrils to induce behavioral changes after
injection into the WT mouse brain [23]. This similarity in
time suggests that seeding of soluble mHTT may indeed
occur in both circumstances. While uptake of free mHTT
has not previously been tested in vivo, a number of in vitro
experiments have shown that free mHTT or HTT fibrils and
protein fragments are taken up by a wide range of cells,
including iPSC-derived neurons [23]. Furthermore, soluble
mHTT, particularly fibrillar forms, is prone to spreading and
therefore the most likely to result in pathological changes
[56, 57]. While free plasma is a source of mHTT, soluble
protein was also detected in all tested immune cells. These
cells could have released mHTT into the organs via multiple
pathways including through exocytosis [28] or the release
of extracellular vesicles [58]. Previous evidence has
demonstrated that both exocytosis and extracellular vesicles
can contribute to mHTT spreading in HD. A role of exo-
cytosis was observed in a Drosophila model of HD where
spreading of aggregates and neuronal loss was prevented by
selective genetic crosses which lead to the elimination of
essential exocytosis proteins [28], while injection of extra-
cellular vesicles derived from HD patient fibroblasts to the
brains of WT mice was shown to induce severe motor
impairments and detection of EM48 positive signal in the
brains of WT mice [9]. Of these two possibilities, extra-
cellular vesicles would best explain the presence of mHTT
within the striatum and cortex of WT(HD) mice as periph-
erally produced vesicles have been demonstrated to cross
the BBB and to enter the CNS [59]. One point of evidence
against this is the lack of detectable soluble mHTT within
peripheral organs. However, it is possible the soluble
mHTT is present but at levels below the sensitivity
threshold of western blot. The possibility that mHTT
aggregates are directly transferred from immune cells is less
likely, as very few reports have described the presence of
vesicles in peripheral immune cells [32] and directly
deposited aggregates would likely be degraded before
causing lasting harm to the cellular elements.
The findings discussed above raise important questions
regarding the possibility of transmission of mHTT in clin-
ical settings. Currently, patients with neurodegenerative
disorders are not excluded from blood or organ donation but
given the accumulating evidence that many pathological
proteins associated with neurodegenerative diseases are
capable of spreading and causing pathological changes
[60, 61], it is important to understand if there is a risk
associated with these procedures. In the context of HD, the
required 6-month period of continuous blood infusion used
in this study makes any clinical risk of transmitting disease
by blood transfusion very low. These findings are in line
with previous reports examining the risk of developing
Alzheimer’s disease in individuals that have received blood
transfusion from patients diagnosed with this disease [62].
While transmission of HD by blood transfusion is improb-
able, the risk after organ transplantation is less clear. It is
possible that transplantation of an organ from an HD patient
could have detrimental effects, as liver transplants from
familial amyloid polyneuropathy and amyotrophic lateral
sclerosis has been shown to result in the presence of
disease-associated proteins in the graft recipients [63, 64].
Based on our results, full-blown disease would still be
extremely unlikely, as toxicity of mHTT in the parabiosis
model was limited. Behavioral testing would be necessary
to draw firm conclusions, but this is rendered impracticable
as the animals of the same pair interact extensively together,
adapting their behavior to their partner, thus making the
discrimination of the results impossible [42].
Contrary to the detrimental effects observed in WT mice,
our data strongly suggests that healthy blood may have a
therapeutic effect on HD mice. In the liver, HD(WT) mice had
half the number of aggregates as either HD(HD) or HD(NP). In
the muscle, WT blood did not impact the number of aggre-
gates but it did significantly improve the mitochondrial
function. A particularly interesting part of this data was the
dose-response pattern where HD(NP) displayed the greatest
difference from WT with slight improvements detected in
HD(HD) and the strongest in HD(WT). Such a pattern of change
was not only present in the periphery but was also detected in
HTT levels in the brain at 6 months where the concentration
of WT HTT and mHTT decreased substantially from NP
mice to same genotype pairs, and from same genotype pairs
to two genotype pairs. The presence of such striking changes
in both the periphery and CNS strongly suggests that the
parabiosis procedure may modulate HTT itself. Over time,
this effect stabilized and by 12 months post-parabiosis, same
genotype couples had a marked increase in both mHTT and
WT HTT. Given the absence of changes in mRNA levels in
the brain, it seems likely that the mechanism involved in
mHTT reduction involves increased protein degradation.
This dose-response pattern was also observed in NeuN levels
in the cortex but other protein changes, such as GAD65/67
5460 M. Rieux et al.
and DARPP32, were only observed in HD(WT) mice. When
the combination of cell counts and differences in protein
levels are examined together, the results are indicative of
functional changes to DARPP32 and Iba1 in the striatum and
GAD65/67 in the cortex, which supports the beneficial effect
of WT blood on HD mice. The changes observed in
DARPP32 are particularly informative, especially when
considered with western blot data of VGLUT1, as both of
these proteins are associated with the corticostriatal pathway.
The changes in DARPP32 protein are supportive of this, but
VGLUT1 alterations in the cortex and striatum indicate that
multiple pathways may be impacted. Parabiosis itself
increases VGLUT1 in the cortex in a manner which is see-
mingly independent of WT blood, while no significant effect
of parabiosis or WT blood is apparent in the striatum. This
may suggest that there are two separate effects: one on pro-
jection neurons of the cortex and one on DARPP32 positive
striatal projection neurons. Overall, the different changes
observed between various proteins imply that multiple
mechanisms are involved in these beneficial changes.
Biomarker studies have reported that the concentration of
mHTT in the CSF correlates well with disease stage and
severity [10], suggesting that a reduction of mHTT in the
CSF would be likely to have clinical benefits. Whether per-
ipheral concentrations of mHTT impact CSF levels is
unclear, recent studies reducing mHTT to 50% in peripheral
organs in a mouse model of HD did not result in any
improvements to central pathology [65]. However, it should
be noted that this particular study did not evaluate whether
HTT/mHTT was reduced within cells of the immune system
and used the Q111 mouse model which presents with a rather
mild phenotype [66]. A second possibility is that the para-
biosis procedure itself contributes to clearance of toxic sub-
stances from the CNS by lowering blood pressure and
thereby favoring efflux of CSF. This would be consistent
with the “dose response” effect observed for some CNS
changes (i.e., HTT and NeuN). Evidence from the literature
is limited but one study of rats in parabiosis measured blood
pressure and failed to detect a decrease. However, this study
was completed with hypertensive and normotensive rats
which decreases the ability to extrapolate to a situation where
both animals are normotensive at the start of the study [67].
The lack of striking differences between zQ175 and WT
animals suggests that this mechanism is unlikely to be
important in the benefits observed, although it is conceivable
that combining the two genotypes could result in hemody-
namic alterations that are not present under basal conditions.
A third possibility would be that blood from the WT mouse
is diluting inflammatory cytokines or other detrimental cir-
culating factors, thereby modifying disease phenotypes. This
hypothesis is supported by several studies which have
described a relationship between peripheral plasma levels of
cytokines and disease progression or HTT levels [19].
Additionally, multiple cytokines have been shown to increase
with disease progression including IL-4, IL-5, and IL-10
[19]. When we measured cytokines in the plasma, we did not
see a significant reduction in HD(WT) mice although WT(HD)
animals had consistently showed a trend towards an increase
in circulating cytokines, suggesting that inflammation may
contribute to the detrimental changes observed.
While further work is required to clarify the mechanism
underlying the beneficial effects of healthy blood on disease-
related features, our findings suggest that some form of blood
transfusion or plasma exchange may result in meaningful
clinical benefits in patients. Due to the amount of time
required for improvements in our model, transfusions alone
would not be sufficient but plasmapheresis, a process similar
to dialysis designed to replace plasma from patients with
healthy plasma, may be of use by either reducing mHTT or
normalizing plasma levels of cytokines [20, 68, 69]. This
method has already been studied for brain rejuvenation,
namely with heterochronic parabiosis between an elderly
mouse and a young mouse [70, 71] and clinical studies are
devoted to this new Fountain of Youth, whose initial results
have demonstrated the safety, tolerability and feasibility of
this intervention [72]. Given the large number of factors
impacted by parabiosis, assessment of the clinical effects of
plasmapheresis in HD would be warranted and may have
implications for other disorders of the CNS.
Taken together, the results of our parabiosis study pro-
vide clear evidence that blood can serve as a vehicle for
mHTT propagation, which leads to mild HD-related
pathology. The most obvious explanation for this propa-
gation is the presence of mHTT in free forms in the plasma
which can then be taken up by cells. Our findings are also of
significant clinical importance in that we have shown that
healthy blood can abrogate a number of pathological fea-
tures of HD mice. This suggests that targeting peripheral
blood circulation may be a novel and effective therapeutic
strategy for HD.
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